Literature DB >> 10490831

Overexpression of the Tpl-2/Cot oncogene in human breast cancer.

G Sourvinos1, C Tsatsanis, D A Spandidos.   

Abstract

Tpl-2/Cot proto-oncogene encodes a serine threonine kinase and was initially cloned as a provirus insertion site in MoMuLV-induced T cell lymphomas in rats. Tpl-2 locus was also shown to be affected by provirus insertion in MMTV-induced mammary carcinomas in mice. The involvement of Tpl-2 in 35 human breast paired tumour specimens versus their corresponding adjacent normal tissue was evaluated. Tpl-2 was found overexpressed in 14 of the 35 breast tumours tested using a semi-quantitative RT - PCR method. Gene amplification was detected in eight out of the 14 specimens overexpressing Tpl-2, suggesting the increased number of copies of Tpl-2 gene as a possible mechanism for Tpl-2 overexpression. Significant association was found between the overexpression of Tpl-2 and stage I of the tumours, indicating that this molecular alteration may be an early event in the development of the disease. Furthermore, overexpression of Tpl-2 was associated with positive progesterone receptor status of the samples. This is the first report on the Tpl-2 oncogene linked to human breast tumours suggesting that it may be a key molecule for the study of human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10490831     DOI: 10.1038/sj.onc.1202891

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  The COOH-terminal domain of wild-type Cot regulates its stability and kinase specific activity.

Authors:  Maria Luisa Gándara; Pilar López; Raquel Hernando; José G Castaño; Susana Alemany
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

2.  Tpl2 inhibitors thwart endothelial cell function in angiogenesis and peritoneal dissemination.

Authors:  Wen-Jane Lee; Keng-Hsin Lan; Chiang-Ting Chou; Yu-Chiao Yi; Wei-Chih Chen; Hung-Chuan Pan; Yen-Chun Peng; Keh-Bin Wang; Yi-Ching Chen; Te-Hsin Chao; Hsing-Ru Tien; Wayne Huey Herng Sheu; Meei-Ling Sheu
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

3.  Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction.

Authors:  U Lehmann; S Glöckner; W Kleeberger; H F von Wasielewski; H Kreipe
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

4.  TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations.

Authors:  Paarth B Dodhiawala; Namrata Khurana; Daoxiang Zhang; Yi Cheng; Lin Li; Qing Wei; Kuljeet Seehra; Hongmei Jiang; Patrick M Grierson; Andrea Wang-Gillam; Kian-Huat Lim
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

5.  Loss of tumor progression locus 2 (tpl2) enhances tumorigenesis and inflammation in two-stage skin carcinogenesis.

Authors:  K L Decicco-Skinner; E L Trovato; J K Simmons; P K Lepage; J S Wiest
Journal:  Oncogene       Date:  2010-10-11       Impact factor: 9.867

6.  Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis.

Authors:  Vasiliki Koliaraki; Manolis Roulis; George Kollias
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

7.  Mutational activation of the MAP3K8 protooncogene in lung cancer.

Authors:  Adam Michael Clark; Steven H Reynolds; Marshall Anderson; Jonathan S Wiest
Journal:  Genes Chromosomes Cancer       Date:  2004-10       Impact factor: 5.006

Review 8.  Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.

Authors:  R Mandal; S Becker; K Strebhardt
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

9.  Tpl2 knockout keratinocytes have increased biomarkers for invasion and metastasis.

Authors:  Kathleen L Decicco-Skinner; Sarah A Jung; Tracy Tabib; J Curtis Gwilliam; Hepzibha Alexander; Sarah E Goodheart; Anand S Merchant; Mengge Shan; Caroline Garber; Jonathan S Wiest
Journal:  Carcinogenesis       Date:  2013-09-25       Impact factor: 4.944

10.  Tpl2 is a key mediator of arsenite-induced signal transduction.

Authors:  Kyung Mi Lee; Ki Won Lee; Ann M Bode; Hyong Joo Lee; Zigang Dong
Journal:  Cancer Res       Date:  2009-10-06       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.